中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 42 Issue 4
Apr.  2026
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2026  >  42(4): 882-889

Association of insulin-like growth factor binding protein-3 gene polymorphism at the rs10225396 locus with susceptibility to hepatocellular carcinoma

DOI: 10.12449/JCH260417
  • 1.

    School of Medicine，Yanbian University，Yanji，Jilin 133000，China

  • 2.

    Department of Infectious Diseases，The Affiliated Hospital of Yanbian University，Yanji，Jilin 133000，China

  • 3.

    Department of Critical Care Medicine，The Affiliated Hospital of Yanbian University，Yanji，Jilin 133000，China

Research funding:

Jilin Provincial Natural Science Foundation (20200201413JC)

More Information
  • Corresponding author: CUI Qingsong， qingsong0206@126.com （ORCID： 0009-0004-6433-8753）
  • Received Date: 2025-10-24
  • Accepted Date: 2025-12-24
  • Published Date: 2026-04-25
    Abstract
  •   Objective  To investigate the association of the single nucleotide polymorphism （SNP） of the insulin-like growth factor binding protein-3 （IGFBP3） gene at rs10225396 （A>G） locus with the susceptibility to hepatocellular carcinoma， as well as its potential molecular regulatory mechanisms， and to provide novel genetic biomarkers and a theoretical basis for early screening and precise targeted therapy for hepatocellular carcinoma.  Methods  A total of 192 patients with hepatocellular carcinoma who were admitted to The Affiliated Hospital of Yanbian University and Yanbian Cancer Hospital from January 2009 to August 2016 were enrolled as experimental group， and 190 healthy individuals who underwent physical examination in Physical Examination Center of Yanbian Hospital during the same period of time were enrolled as control group. Peripheral blood samples were collected from all subjects， and after DNA was extracted from whole blood， the DNA samples meeting quality standards were sent to Beijing Genomics Institute Research Center Co.， Ltd.， for Mass ARRAY mass spectrometry， while genotyping was completed. The independent-samples t test was used for comparison of continuous data between two groups， and the chi-square test was used for comparison of categorical data between two groups. A binary Logistic regression model was used to analyze the association of the SNP of theIGFBP3 gene at rs10225396 locus with the susceptibility to hepatocellular carcinoma， and odds ratio （OR） and 95% confidence interval （CI） were calculated to assess the risk of developing hepatocellular carcinoma in individuals carrying different genotypes.  Results  There were two alleles （G and A） at the rs10225396 locus of the IGFBP3 gene， yielding the three genotypes of AA， AG， and GG， and its genotype distribution was consistent with the Hardy-Weinberg equilibrium （χ²=0.072， P=0.789）. The stratified genetic analysis showed that carriers of the IGFBP3 rs10225396 AA genotype had a significant increased risk of hepatocellular carcinoma among individuals of age <63 years， male sex， smoking history， drinking history， and the Chinese Korean population （all P<0.001）. The binary Logistic regression analysis showed that after adjustment for related risk factors in the codominant model， the population with genotype AG and GG had a significant reduction in the risk of hepatocellular carcinoma compared with the population with genotype AA （P<0.001）， and in the dominant model， the population with genotype AG+GG had a significant reduction in the risk of hepatocellular carcinoma compared with the population with genotype AA （P<0.001）.  Conclusion  Through a genotyping analysis of hepatocellular carcinoma patients and healthy individuals in Yanbian Korean Autonomous Prefecture of Jilin Province， China， this study shows that genotype AA at rs10225396 locus of the IGFBP3 gene is significantly associated with the susceptibility to hepatocellular carcinoma， and this genotype can significantly increase the risk of developing hepatocellular carcinoma with the presence of specific risk factors， which provides a potential genetic marker for early screening and precise treatment of hepatocellular carcinoma.

     

    • FullText(HTML)
  • loading
    • References(24)
  • [1]
    Chinese Society of Liver Cancer, Chinese Anti-Cancer Association. Chinese expert consensus on multidisciplinary treatment of liver cancer(2025)[J]. J Clin Hepatol, 2025, 41( 7): 1279- 1286. DOI: 10.12449/JCH250709.

    中国抗癌协会肝癌专业委员会. 中国肝癌多学科综合治疗专家共识(2025年版)[J]. 临床肝胆病杂志, 2025, 41( 7): 1279- 1286. DOI: 10.12449/JCH250709.
    [2]
    National Health Commission of the People’s Republic of China. Standard for diagnosis and treatment of primary liver cancer(2024 edition)[J]. J Clin Hepatol, 2024, 40( 5): 893- 918. DOI: 10.12449/JCH240508.

    中华人民共和国国家卫生健康委员会. 原发性肝癌诊疗指南(2024年版)[J]. 临床肝胆病杂志, 2024, 40( 5): 893- 918. DOI: 10.12449/JCH240508.
    [3]
    FAN J, GAO Q. New progress in liver cancer diagnosis and treatment: Guidelines lead standardization, inno-vations empower precision[J]. Chin J Dig Surg, 2024, 23( 2): 197- 203. DOI: 10.3760/cma.j.cn115610-20240112-00019.

    樊嘉, 高强. 肝癌诊疗新进展: 指南引领规范 创新赋能精准[J]. 中华消化外科杂志, 2024, 23( 2): 197- 203. DOI: 10.3760/cma.j.cn115610-20240112-00019.
    [4]
    LONG X, ZHANG L, WANG WQ, et al. Response of scalp and skull metastasis to anti-PD-1 antibody combined with regorafenib treatment in a sorafenib-resistant hepatocellular carcinoma patient and a literature review[J]. Onco Targets Ther, 2022, 15: 703- 716. DOI: 10.2147/OTT.S365652.
    [5]
    RUMGAY H, ARNOLD M, FERLAY J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040[J]. J Hepatol, 2022, 77( 6): 1598- 1606. DOI: 10.1016/j.jhep.2022.08.021.
    [6]
    GRIMBERG A, COHEN P. Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis[J]. J Cell Physiol, 2000, 183( 1): 1- 9. DOI: 3.0.CO;2-J">10.1002/(SICI)1097-4652(200004)183: 1<1:: AID-JCP1>3.0.CO;2-J.
    [7]
    ZHANG YZ, LV X. IGFBP3 modulation of tumor pathogenesis and cell signaling pathways(Review)[J]. Oncol Lett, 2025, 30( 2): 379. DOI: 10.3892/ol.2025.15125.
    [8]
    BOYLE AP, HONG EL, HARIHARAN M, et al. Annotation of functional variation in personal genomes using RegulomeDB[J]. Genome Res, 2012, 22( 9): 1790- 1797. DOI: 10.1101/gr.137323.112.
    [9]
    MAURANO MT, HUMBERT R, RYNES E, et al. Systematic localization of common disease-associated variation in regulatory DNA[J]. Science, 2012, 337( 6099): 1190- 1195. DOI: 10.1126/science.1222794.
    [10]
    RAM M, FRASER MR, VIEIRA DOS SANTOS J, et al. The genetic and molecular drivers of multiple myeloma: Current insights, clinical implications, and the path forward[J]. Pharmgenomics Pers Med, 2024, 17: 573- 609. DOI: 10.2147/PGPM.S350238.
    [11]
    BICK AG, METCALF GA, MAYO KR, et al. Genomic data in the all of us research program[J]. Nature, 2024, 627( 8003): 340- 346. DOI: 10.1038/s41586-023-06957-x.
    [12]
    WANG JB, PANG GSY, CHONG SS, et al. SNP web resources and their potential applications in personalized medicine[J]. Curr Drug Metab, 2012, 13( 7): 978- 990. DOI: 10.2174/138920012802138552.
    [13]
    LU QC, LAO XX. Research progress of cervical cancer susceptibility gene polymorphism[J]. Chin J Fam Plan Gynecotokology, 2023, 15( 4): 14- 18. DOI: 10.3969/j.issn.1674-4020.2023.04.04.

    陆庆春, 劳小霞. 宫颈癌易感基因多态性的研究进展[J]. 中国计划生育和妇产科, 2023, 15( 4): 14- 18. DOI: 10.3969/j.issn.1674-4020.2023.04.04.
    [14]
    ZHU XN, WANG ZG, QIU XQ, et al. Associations between single nucleotide polymorphisms in RYBP and the prognosis of hepatocellular carcinoma in a Chinese population[J]. Carcinogenesis, 2017, 38( 5): 532- 540. DOI: 10.1093/carcin/bgx031.
    [15]
    CAO GW. Cancer in China: Epidemiological characteristics, current prophylaxis and treatment, and future strategy[J]. Acad J Nav Med Univ, 2025, 46( 3): 279- 290. DOI: 10.16781/j.CN31-2187/R.20250050.
    [16]
    PAN ZL, YIN HM, TANG HY, et al. Correlation analysis of single nucleotide polymorphisms of HLA gene with clinicopathological features and postoperative prognosis of primary hepatocellular carcinoma[J]. Med J Chin People’s Liberation Army, 2025, 50( 11): 1390- 1397. DOI: 10.11855/j.issn.0577-7402.0604.2025.0211.

    潘正龙, 殷浩铭, 唐豪言, 等. HLA基因单核苷酸多态性与原发性肝细胞癌临床病理特征及术后预后的相关性分析[J]. 解放军医学杂志, 2025, 50( 11): 1390- 1397. DOI: 10.11855/j.issn.0577-7402.0604.2025.0211.
    [17]
    WANG YY, ZHANG XP, LIU ZY, et al. Association analysis of SLC16A11 SLC16A13 gene polymorphism and hepatitis B-related liver cancer[J]. J Hebei Med Univ, 2023, 44( 1): 16- 19, 67. DOI: 10.3969/j.issn.1007-3205.2023.01.004.

    王莹莹, 张贤培, 刘震阳, 等. SLC16A11、SLC16A13基因多态性与乙型肝炎相关性肝癌的关联性分析[J]. 河北医科大学学报, 2023, 44( 1): 16- 19, 67. DOI: 10.3969/j.issn.1007-3205.2023.01.004.
    [18]
    WANG YR, WANG C, LIU XZ, et al. Mechanism of emodin induces apoptosis of gastric cancer cells by intervening insulin-like growth factor-1 receptor[J]. Pharmacol Clin Chin Mater Med, 2024, 40( 12): 60- 66. DOI: 10.13412/j.cnki.zyyl.20240612.002.

    王燕如, 王超, 刘秀珠, 等. 大黄素干预胰岛素生长因子受体诱导胃癌细胞凋亡的作用机制[J]. 中药药理与临床, 2024, 40( 12): 60- 66. DOI: 10.13412/j.cnki.zyyl.20240612.002.
    [19]
    TIAN J, FU Y, SUN Y, et al. The roles of Insulin-like growth factor signaling axis and its inhibitors in tumors[J]. J Northwest Univ Nat Sci Ed, 2024, 54( 5): 876- 888. DOI: 10.16152/j.cnki.xdxbzr.2024-05-010.

    田静, 付瑶, 孙钰, 等. 胰岛素样生长因子信号轴与其抑制剂在肿瘤中的作用[J]. 西北大学学报(自然科学版), 2024, 54( 5): 876- 888. DOI: 10.16152/j.cnki.xdxbzr.2024-05-010.
    [20]
    ZHANG NC, ZHANG L, PENG Y, et al. Yak IGFBP3 promotes hepatocyte proliferation through PI3K-Akt signaling pathway[J]. Gene, 2024, 917: 148460. DOI: 10.1016/j.gene.2024.148460.
    [21]
    XIA L, RUAN M, HUANG Q, et al. Abnormal expression of IGFBP3 gene and prognosis of hepatocellular carcinoma[J]. China Health Stand Manag, 2024, 15( 16): 135- 141. DOI: 10.3969/j.issn.1674-9316.2024.16.032.

    夏磊, 阮梅, 黄倩, 等. IGFBP3基因的异常表达与肝细胞癌的预后关系[J]. 中国卫生标准管理, 2024, 15( 16): 135- 141. DOI: 10.3969/j.issn.1674-9316.2024.16.032.
    [22]
    ZHANG PR, LI HG, ZHUO JY, et al. Remodeling of the internal environment in hepatocellular carcinoma: A synergistic mechanism of exogenous exposure[J]. Biomed Transform, 2025, 6( 2): 8- 13. DOI: 10.12287/j.issn.2096-8965.20250202.

    张培儒, 李辉港, 卓建勇, 等. 肝癌内环境重塑: 外源性暴露的协同作用机制[J]. 生物医学转化, 2025, 6( 2): 8- 13. DOI: 10.12287/j.issn.2096-8965.20250202.
    [23]
    CHO EJ, CHUNG GE, YOO JJ, et al. The association between alcohol consumption and the risk of hepatocellular carcinoma according to glycemic status in Korea: A nationwide population-based study[J]. PLoS Med, 2023, 20( 6): e1004244. DOI: 10.1371/journal.pmed.1004244.
    [24]
    SHU WX, LIU L, JIANG JJ, et al. Dietary patterns and hepatocellular carcinoma risk: A systematic review and meta-analysis of cohort and case-control studies[J]. Nutr Metab, 2024, 21( 1): 47. DOI: 10.1186/s12986-024-00822-y.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(5)  / Tables(4)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (30) PDF downloads(8) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return